Concord Biotech Q1 Results
- BSE: 543960
- NSE: CONCORDBIO
- ISIN: INE338H01029
- Sector: Biotechnology & Drugs
BSE
1,448.05
-5.40 (-0.37%)
-5.40 (-0.37%)Volume1.07 L
Updated: Fri 14 Aug, 2026 | 14:57:17
NSE
1,447.10-7.40 (-0.51%)
-7.40 (-0.51%)Volume91.03 K
Updated: Fri 14 Aug, 2026 | 14:42:36
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q1 Results Highlights
- Total Income₹257.49 Cr.(26.23%)
- Operating Profit₹64.28 Cr.(47.35%)
- Profit After Tax₹58.53 Cr.(32.84%)
- Operating Margin24.96%(16.74%)
Note: Comparison is on YoY basis
Quarterly - Concord Biotech Q1 Results
*All figures in crores except per share values
| Fiscal Period | Jun 26 | Mar 26 | QoQ Comp | Jun 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 193.21 | 227.09 | -14.92% | 147.70 | 20.48% |
| Depreciation/ Amortization | 18.10 | 19.54 | -7.39% | 13.18 | 1.82% |
| Operating Income | 64.28 | 98.99 | -35.07% | 68.10 | 47.35% |
| Net Income | 58.53 | 88.79 | -34.09% | 59.59 | 32.84% |
| Other Operating Expenses Total | 42.46 | 44.20 | -3.93% | 54.56 | 41.01% |
| Net Income Before Taxes | 78.34 | 114.08 | -31.32% | 79.52 | 33.39% |
| Total Revenue | 257.49 | 326.08 | -21.03% | 215.80 | 26.23% |
| Selling/ General/ Admin Expenses Total | 43.64 | 47.77 | -8.65% | 31.66 | 15.15% |
| Diluted Normalized EPS | 5.52 | 8.70 | -36.54% | 5.70 | 31.12% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.